Liquid Biopsy Market: Discussion on Radically Improved Cancer Management and Research

1
Liquid Biopsy Market Analysis and Forecasts
ReportByInsight Pharma Reports
Single User License US 1595 Published Feb 2015

• Browse more reports on Life Sciences _at_
• www.rnrmarketresearch.com/reports/life-sciences
  .

2
Liquid Biopsy Market Analysis and Forecasts Report
Cancer diagnostics based on measuring biomarkers
in tissue samples has already in the past decade
provided revolutionary advances in diagnosis,
prognosis, and therapy selection. A major
drawback of the tissue-based approach centers on
the need for invasive surgical procedures in
sample collection, which in a great many
instances preclude following the progression or
regression of disease during therapy. In recent
years, an impressive number of cancer biomarker
researchers have turned their attention to the
analysis of markers present in biological fluids,
which can be collected with minimal invasiveness
and permit following the disease over time. This
highly dynamic field has come to be called liquid
biopsy. In the past few years a significant and
growing number of startups and several major
companies have taken up the challenge of
commercializing and offering liquid biopsy
products and services to the market View
Complete Report _at_ http//www.rnrmarketresearch.com
/liquid-biopsy-an-emerging-market-for-radically-im
proved-cancer-management-market-report.html .
RnRMarketResearch.com sales_at_rnrmarketresearch
.com 1 888 391 5441
3
Liquid Biopsy Market Analysis and Forecasts Report
These procedures, for the most part, query blood
samples for information to be gleaned from
circulating tumor cells (CTCs), circulating tumor
DNA (ctDNA) fragments, and extracellular vesicles
(EVs). CTCs have the longest history as subjects
for liquid biopsy. Indeed, one decade-old
commercial product has already garnered FDA
approval for in vitro diagnostic use. Circulating
tumor DNA, a more recent entry on the liquid
biopsy scene, is fast becoming an alternative or
adjunct to CTC assays. EVs are the newest and
least developed of the three liquid biopsy sample
sources, and while highly promising their
ultimate value has yet to be fully
established. The report delves deeply into
recent progress and emerging trends in this
highly dynamic area of research and commerce.
Following an introductory chapter that sets the
stage for what is to follow, Chapter 2 provides a
survey of historical and evolutionary aspects of
liquid biopsy, and provides required background
and definitions helpful in understanding
subsequent material. Chapter 3 covers basic
research activities arranged according to the
three aforementioned analyte classes (CTCs,
ctDNA, and EVs).
RnRMarketResearch.com sales_at_rnrmarketresearch
.com 1 888 391 5441
4
Liquid Biopsy Market Analysis and Forecasts Report
CTCs, the first such entities on the liquid
biopsy scene, have accounted for much of whats
been learned to date. However, the relative ease
of isolating cell-free DNA has quickened research
activity in this field, and ready access to ctDNA
has provided important insights that enhance and
complement those derived from CTCs. EVs, though a
recent arrival on the liquid biopsy scene, are
rising rapidly in importance based on their
perceived ability to add yet another important
perspective to cancer diagnostics. Purchase a
Copy of this Report _at_ http//www.rnrmarketresearch
.com/contacts/purchase?rname311069 .
RnRMarketResearch.com sales_at_rnrmarketresearch
.com 1 888 391 5441
5
Liquid Biopsy Market Analysis and Forecasts Report
Chapter 4 examines commercial activity in the
field, including brief profiles of relevant
companies and status of current and forthcoming
product offerings. Companies active in CTCs
include AdnaGen, Angle, ApoCell, Biocept,
Biofluidica, Clearbridge Biomedics, Cynvenio,
Cytolumina, CytoTrack, Diagnologix, Epic
Sciences, Fluxion Biosciences, iCellate, Janssen
Diagnostics, Qiagen, Rarecells SAS, Silicon
Biosystems, and SRI International. Biocept and
Cynvenio exemplify companies that augment their
CTC assays with ctDNA analysis. Companies
focused on ctDNA include Agena Bioscience, Boreal
Genomics, Chronix Biomedical, Genomic Health,
Guardant Health, Inivata, Molecular MD, Myriad
Genetics, Natera, Personal Genome Diagnostics,
Sysmex Inostics, and Trovagene. Those active in
the EV segment include Exosome Diagnostics,
Exosome Sciences, and HansaBiomed OU. Chapter 5,
which deals with market dynamics in the liquid
biopsy space, includes commentary on the
competitive environment, market size estimates
and five-year revenue projections, tabulation and
discussion of deal activity, and results from a
market survey of more than 100 individuals active
in the field.
RnRMarketResearch.com sales_at_rnrmarketresearch
.com 1 888 391 5441
6
Liquid Biopsy Market Analysis and Forecasts Report
Chapter 6 of the report examines some emerging
trends that may affect the future development,
acceptance, and market growth of liquid biopsy.
Of particular interest are trends in government
regulation that could possibly limit growth of
the field, and even in the overall molecular
diagnostics market. The report also discusses
issues surrounding the relative merits of the
three categories of liquid biopsy samples, and
ways in which they may be competitive or
complementary. Finally, the chapter examines
important trends relevant to cancer drug
resistance and metastasis. The final chapter
contains transcripts from extended interviews
with six individuals who are highly knowledgeable
in the liquid biopsy field. Inquire for discount
on this report _at_ http//www.rnrmarketresearch.com/
contacts/discount?rname311069 .
RnRMarketResearch.com sales_at_rnrmarketresearch
.com 1 888 391 5441
7
Liquid Biopsy Market Analysis and Forecasts Report

• These are
• Nicholas Dracopoli, Ph.D., Vice President
  Oncology Translational Research, Janssen
  Pharmaceuticals
• Paul Dempsey, Ph.D., Chief Scientific Officer,
  Cynvenio Biosystems
• Johan Skog, Ph.D., CSO and Founding Scientist,
  Exosome Diagnostics
• Lidia Sambucetti, PhD, Sr. Director of Cancer
  Biology, and Ted Ira, Director of Sales, SRI
  Biosciences Div.
• Harry Glorikian, Life Sciences Consultant
• Executive Summary
• This report, Liquid Biopsy An Emerging Market
  for RadicallyImproved Cancer Management, deals
  with recent progress and new directions in this
  highly dynamic emerging modality for cancer
  research and in vitro diagnostics more

RnRMarketResearch.com sales_at_rnrmarketresearch
.com 1 888 391 5441
8
Liquid Biopsy Market Analysis and Forecasts Report
Background and history In the past, biopsied
tissue has been evaluated for malignancy by
highly trained pathologists peering through
microscopes and applying hard-won heuristic
knowledge in pattern recognition. Some tissue
micrographs yield unequivocal results, but many
do not. Instead, many provide ambiguous data that
can easily confound interpretation. The advent of
routine immunohistochemistry improved that state
of affairs somewhat by adding the ability to
visualize the presence and distribution of
certain cellular antigens more Basic research
The availability of sophisticated analytical
tools for analyzing the contents of cancer cells,
for detecting genetic variants at extremely low
allele frequencies, and for isolating
extracellular vesicles, has in recent years
triggered a great deal of research using liquid
biopsy to yield valuable knowledge not readily
accessible before liquid biopsy became available.
CTCs, the first such entities on the liquid
biopsy scene, have accounted for much of whats
been learned to date more
RnRMarketResearch.com sales_at_rnrmarketresearch
.com 1 888 391 5441
9
Liquid Biopsy Market Analysis and Forecasts Report
Commercial aspects of liquid biopsy Janssen
Diagnostics CellSearch CTC enumeration system
dates back more than a decade, and the company
has enjoyed, essentially, a monopoly in the
liquid biopsy market, however small its been.
Recent years have seen rapid growth in the number
of companies entering the market, many of which
are backed with substantial venture capital
funding more. Market dynamics Although liquid
biopsy shows great potential to extend the
capabilities of tissue biopsy and possibly even
replace it, the modality is still in its early
days. Considerable inputs of effort and
investment will be required before the field can
mature and achieve widespread, routine use in
oncology clinical practice more Trends Chapte
r 6 of the report examines some emerging trends
that may affect the future development,
acceptance, and market growth of liquid biopsy.
Of particular interest are trends in government
regulation that could limit growth in liquid
biopsy, and indeed in the overall molecular
diagnostics market more
RnRMarketResearch.com sales_at_rnrmarketresearch
.com 1 888 391 5441
10
Liquid Biopsy Market Analysis and Forecasts Report

• For more details contact Mr. Ritesh Tiwari
  sales_at_rnrmarketresearch.com / 18883915441

RnR Market Research RnRMarketResearch.com, an
online repository of market  research reports,
offers in-depth analysis of over 5000 market
segments. RnR  Market Research library has
syndicated reports by leading market research 
publishers across the globe.